Stocks and InvestingStocks and Investing
Fri, December 2, 2022
Thu, December 1, 2022
Wed, November 30, 2022
Tue, November 29, 2022

Akash Tewari Maintained (BMRN) at Strong Buy with Increased Target to $120 on, Nov 29th, 2022


Published on 2024-10-28 00:21:50 - WOPRAI, Akash Tewari
  Print publication without navigation


Akash Tewari of Jefferies, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Increased Target from $100 to $120 on, Nov 29th, 2022.

Akash has made no other calls on BMRN in the last 4 months.



There are 8 other peers that have a rating on BMRN. Out of the 8 peers that are also analyzing BMRN, 1 agrees with Akash's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Luca Issi of "RBC Capital" Maintained at Hold with Increased Target to $95 on, Thursday, October 13th, 2022


These are the ratings of the 7 analyists that currently disagree with Akash


  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Increased Target to $110 on, Monday, October 31st, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $113 on, Thursday, October 27th, 2022
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $110 on, Thursday, October 27th, 2022
  • Jessica Fye of "JP Morgan" Maintained at Buy with Decreased Target to $112 on, Monday, October 24th, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $128 on, Tuesday, August 9th, 2022
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $125 on, Thursday, August 4th, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $122 on, Thursday, August 4th, 2022